Loading...
Loading...
THRX| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 15.5M |
| Operating I/L | -15.5M |
| Other Income/Expense | 1.8M |
| Interest Income | 0.0M |
| Pretax | -13.7M |
| Income Tax Expense | 1.7M |
| Net Income/Loss | -15.4M |
Theseus Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of targeted therapies for cancer treatment. The company's lead product candidate, THE-630, is a pan-KIT inhibitor designed for the treatment of gastrointestinal stromal tumors and is currently in Phase I clinical trial. Additionally, Theseus Pharmaceuticals is developing a fourth-generation EGFR inhibitor to address drug resistance mutations in non-small cell lung cancer patients. The company's focus on developing therapies targeting key driver oncogenes aims to address the growing need for effective treatments for cancer patients.
